CFR up +1.02% percent right now. $CFR High is at 82.00 and

New Post Public Reply Private Reply Replies (0) Message Board
Lucky Jimmy
CFR up +1.02% percent right now. $CFR High is at 82.00 and the Low 80.69 with current volume of 125,239.

Recent News posted below.

CFR Cullen/Frost Bankers Recent Headline News

Cullen/Frost Bankers Earnings In Retrospect: Up 1.8% in the Last 12 Days (CFR)
Comtex SmarTrend(R) - Mon Nov 10, 10:12AM CST
12 days ago, on October 29th, 2014, Cullen/Frost Bankers (NYSE:CFR) reported its earnings. Analysts, on average, expected earnings of $1.11 per share on sales of $288.7 million. The company actually reported EPS of $1.19 on sales of $262.7 million, beating EPS estimates by $0.08 and missing revenue estimates by $26.0 million. Since the company's report, shares of Cullen/Frost Bankers have risen from $79.73 to $81.13, representing a gain of 1.8% in the past 12 days.
CFR: 81.47 (+0.34)

Cullen/Frost Bankers declares $0.51 dividend
Seeking Alpha - at Seeking Alpha - Thu Oct 30, 5:24PM CDT

CFR: 81.47 (+0.34)

Cullen/Frost Bankers Declares Quarterly Cash Dividend For Common Stock And Preferred Stock
PR Newswire - Thu Oct 30, 2:55PM CDT
The Cullen/Frost Bankers, Inc. board of directors declared a fourth quarter cash dividend of $.51 per common share. The dividend is payable December 15, 2014 to shareholders of record on November 28 of this year.
CFR: 81.47 (+0.34)

Cullen/Frost Q3 Earnings Beat on High Revenues; Shares Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Oct 30, 10:10AM CDT
Shares of Cullen/Frost Bankers, Inc. (CFR) rose 1.03% to close at $79.73, after the company posted encouraging third-quarter 2014 results on Wednesday, before the opening bell.
CFR: 81.47 (+0.34), BOKF: 68.78 (+0.50), PB: 60.49 (+0.37), TCBI: 61.58 (+0.01)

Cullen/Frost Bankers' (CFR) CEO Richard Evans on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Wed Oct 29, 3:30PM CDT

CFR: 81.47 (+0.34)

Cullen/Frost Bankers beats by $0.08, misses on revenue
Seeking Alpha - at Seeking Alpha - Wed Oct 29, 8:11AM CDT

CFR: 81.47 (+0.34)

Cullen/Frost Reports Strong Third Quarter Results
PR Newswire - Wed Oct 29, 8:00AM CDT
Cullen/Frost Bankers, Inc. (NYSE:CFR) today reported strong third quarter 2014 results, including significant net income, loan and deposit growth.
CFR: 81.47 (+0.34)

Notable earnings before Wednesday’s open
Seeking Alpha - at Seeking Alpha - Tue Oct 28, 4:30PM CDT

AUO: 4.84 (-0.02), PSXP: 67.12 (-0.51), GHM: 33.64 (-0.05), CTCM: 6.20 (+0.05), HSY: 96.46 (+0.03), RYAM: 26.41 (-1.56), AIT: 49.32 (-0.01), AMED: 25.13 (+0.34), MRGE: 3.18 (+0.12), RL: 171.91 (-2.09), JLL: 139.91 (+0.44), CFR: 81.47 (+0.34), SPW: 92.66 (-0.20), CKSW: 7.43 (-0.11), IACI: 65.83 (+0.13), DXYN: 7.55 (+0.01), ROL: 32.50 (+0.03), NVMI: 10.64 (+0.27), PSX: 74.69 (-0.01), ETN: 69.23 (+0.06), RES: 15.68 (-0.47), HES: 83.28 (-1.58), EXC: 37.60 (-0.17), COT: 6.54 (+0.17), SEE: 38.84 (-0.05), VLY: 9.99 (+0.01), MHFI: 90.47 (+0.53), WLP: 125.72 (+1.57), UAM: 8.85 (-0.13), ADP: 84.94 (+0.56), PX: 126.18 (-0.49), STM: 6.88 (+0.04), CCJ: 19.33 (+0.58), ALLY: 22.78 (+0.09), GRMN: 55.53 (+0.83), SPWR: 30.49 (+0.27), PAG: 47.00 (+0.01), H: 57.76 (+0.23), WEC: 49.63 (+0.37), ARW: 57.67 (+0.19), CMC: 16.69 (-0.32), BDC: 71.65 (+0.90), TEL: 61.47 (-0.65), ACCO: 8.87 (+0.32), AVX: 14.08 (-0.06), LFUS: 97.89 (+0.41), BAH: 25.90 (+0.16), UBSI: 35.48 (+0.33), ALKS: 52.70 (+1.70), SO: 47.51 (+0.38), WM: 49.53 (+0.08), EVER: 19.06 (+0.11), ISSI: 13.88 (+0.23), GT: 25.31 (+0.16), SKYW: 12.37 (+0.46), TFX: 113.99 (+0.09), SODA: 21.35 (-0.65), MTH: 37.25 (-0.23), OMG: 27.04 (+0.34), PB: 60.49 (+0.37)

Texas Capital Beats on Q3 Earnings & Revenues, Shares Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Oct 24, 11:40AM CDT
Texas Capital's (TCBI) shares gained nearly 2% in a day's trading following its third-quarter 2014 earnings release on Wednesday after the market closed.
CFR: 81.47 (+0.34), BOKF: 68.78 (+0.50), PB: 60.49 (+0.37), TCBI: 61.58 (+0.01)

Cullen/Frost Bankers, Inc. Hosts Third Quarter 2014 Earnings Conference Call
PR Newswire - Mon Oct 20, 3:01PM CDT
Cullen/Frost Bankers, Inc. (NYSE: CFR) will host a conference call on Wednesday, October 29, 2014 to discuss third quarter 2014 earnings.
CFR: 81.47 (+0.34)

Will This Ratings Upgrade Help Cullen/Frost Bankers (CFR) Stock Today?
at The Street - Thu Oct 16, 7:34AM CDT
Cullen/Frost Bankers (CFR) was upgraded to 'market perform' from 'underperform' at BMO Capital.
CFR: 81.47 (+0.34)

Upgrade Alert for Cullen/Frost Bankers (CFR)
Comtex SmarTrend(R) - Thu Oct 16, 7:05AM CDT
Cullen/Frost Bankers (NYSE:CFR) was upgraded from Underperform to Market Perform at BMO Capital today. The stock closed yesterday at $71.81 on volume of 539,000 shares, above average daily volume of 326,000. Over the past year, Cullen/Frost Bankers has traded in a range of $69.82 to $81.73 and closed yesterday at $71.81, 3% above that low. The 200-day and 50-day moving averages have moved 0.01% lower and 0.19% lower over the past week, respectively.
CFR: 81.47 (+0.34)

AGYS, BGMD, CFR Expected To Be Down Before Next Earnings Releases
M2 - Fri Oct 10, 3:03AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring the performance of all stocks with earnings being released in the coming weeks and determining how the stocks have performed Before their last 12 quarterly, 6 quarterly and December earnings reports. Agilysys Inc (NASDAQ:AGYS), BG Medicine Inc (NASDAQ:BGMD), CULLEN/FROST BANKERS, INC (NYSE:CFR) are all expected to be Down Before their earnings are released. The movement of stock prices in the days and weeks leading to and following these earnings announcements may follow a predictable pattern. Most companies stock price histories show random or unpredictable movements around earnings dates. But some seem to repeat the same pattern quarter after quarter, year after year. The # of Reports in the table below shows how many previous quarterly reports comprise the indicator that predicts how a stock will act after its earnings are released. The specific technology used to make these predictions is available for a low monthly fee at http://www.squeezetrigger.com/services/strat/mh.php . The following stocks are expected to go Down Before earnings are released Thursday:
BGMD: 0.45 (+0.03), CFR: 81.47 (+0.34), AGYS: 11.40 (+0.04)

Cullen/Frost Rides High on Organic Growth; Should You Hold? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Oct 03, 10:20AM CDT
On Sep 25, 2014, we issued an updated research report on Cullen/Frost Bankers, Inc. (CFR).
CFR: 81.47 (+0.34), BOKF: 68.78 (+0.50), OPB: 27.00 (+0.01), TCBI: 61.58 (+0.01)

Prosperity Bancshares' Top Line Grows: Should You Hold? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 29, 10:30AM CDT
On Sep 2, 2014, we issued an updated research report on Prosperity Bancshares (PB).
CFR: 81.47 (+0.34), BOKF: 68.78 (+0.50), OPB: 27.00 (+0.01), PB: 60.49 (+0.37)

Citizens Bank's IPO Closes Up 7% After Disappointing Opening
at The Street - Wed Sep 24, 3:28PM CDT
The initial public offering for Citizens Bank was described Wednesday as the 'anti-Alibaba.' But after a weak start, the stock closed up over 7% for the day.
KRE: 40.51 (+0.10), CFR: 81.47 (+0.34), BXS: 22.82 (+0.27), BHLB: 25.40 (-0.26), USB: 43.85 (+0.04), CFG: 23.97 (unch), UBNK: 14.10 (-0.27), RBS: 11.99 (+0.09), BABA: 119.04 (+4.48)

Cullen/Frost (CFR) Hits 52-Week High on Organic Growth - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 22, 1:57PM CDT
Shares of Cullen/Frost Bankers, Inc. (CFR) crafted a new 52-week high, touching $81.73 on Sep 19.
CFR: 81.47 (+0.34), GABC: 29.62 (-0.05), BANC: 11.73 (+0.11), MOFG: 27.30 (+0.15)

BancFirst (BANF) Reaches 52-Week High on Strong Q2 Earnings - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Aug 26, 10:35AM CDT
Shares of BancFirst Corp. (BANF) hit a new 52-week high of $64.70 on Aug 25, riding on a strong growth momentum.
COWN: 4.09 (+0.02), CFR: 81.47 (+0.34), BANF: 66.54 (+0.08), OPB: 27.00 (+0.01)

Earnings Flashback: Since Reporting Quarterly Results 2 Weeks Ago Cullen/Frost Bankers Is Down 3.7% (CFR)
Comtex SmarTrend(R) - Mon Aug 18, 8:25AM CDT
19 days ago, on July 30th, 2014, Cullen/Frost Bankers (NYSE:CFR) reported its earnings. Analysts, on average, expected earnings of $1.02 per share on sales of $275.0 million. The company actually reported EPS of $1.07 on sales of $252.2 million, beating EPS estimates by $0.05 and missing revenue estimates by $22.8 million. Shares of Cullen/Frost Bankers have slipped from $79.40 to $76.49, representing a loss of 3.7%, since the company reported earnings 19 days ago.
CFR: 81.47 (+0.34)

Texas Capital (TCBI) Shows Stability on Organic Growth - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Aug 11, 4:00PM CDT
On Aug 4, 2014, we issued an updated research report on Texas Capital Bancshares Inc. (TCBI). This commercial bank recently reported impressive second-quarter 2014 results.
CFR: 81.47 (+0.34), BANF: 66.54 (+0.08), OPB: 27.00 (+0.01), TCBI: 61.58 (+0.01)
Scroll down for more posts ▼

Top 10 Most Recent News Articles

What to Expect: Your First Therapy Session Insights

Updated Category News Views 220

Starting With the Unknown: The Therapy Journey Begins Rolling into that first therapy session can feel like walking into a mystery with no clues. You're not alone if it stirs up some nerves—most folks feel the same, especially when it's your first rodeo in mental health support. That's where Cody Luke and David Spencer of Luke and Spencer Behavioral Health, based out in...

Continue Reading
CapCut's Role in AI-Assisted Small Biz Marketing

Updated Category News Views 0

In today's fast-paced digital world, small businesses lament the constant hustle to stay relevant online. This juggling act with limited resources often makes effective marketing feel like a high-wire circus performance. Enter AI tools, promising to lighten the load, and CapCut stands out as a game-changer. AI Tools Revolutionizing Small Business Marketing Amid growing...

Continue Reading
Apalutamide Boosts Outlook for Prostate Cancer Treatment

Updated Category News Views 90

Fresh Findings on High-Risk Prostate Cancer Treatments In an industry that often feels like a game of chess, Johnson & Johnson's recent news unveils another one of their strategic moves with the announcement of breakthrough results from their Phase 3 PROTEUS substudy. Turns out, ERLEADA®, their apalutamide treatment, isn't just another pawn; it's a potential...

Continue Reading
CSTS Unveils PremierX in NYC: A Bold Entertainment Move

Updated Category News Views 228

Welcome to the New Era of Entertainment Out of the blockbusters and into the open air, eh? On October 30, 2026, CSTS Enterprises flipped the New York skyline into a canvas for their grand kickoff of PremierXTM—a live entertainment brand poised to redefine how we gobble up our music, sport, and art. Now, there's a shot of adrenaline New Yorkers weren't exactly begging...

Continue Reading
Amgen's IMDELLTRA® Shows Promise in SCLC Battle

Updated Category News Views 408

Breakthrough Results in SCLC Treatment For years, small cell lung cancer (SCLC) has been the unruly beast in the oncology world, defying treatment advances and keeping survival rates stubbornly low. This nasty foe might just have met its match, folks. Amgen (NASDAQ:AMGN) announced results from their Phase 3 DeLLphi-305 trial that show their drug IMDELLTRA®, when teamed...

Continue Reading
TORRAS Cases Balance Protection with Slim Design for 2026

Updated Category News Views 39

Are Slim iPhone Cases Really Protecting Your Investment? Anyone who's dropped a brand-new phone knows the pain of watching your investment smack the concrete. But hey, welcome to 2026, where Consumer365's latest rundown on iPhone protective gear turns the spotlight on TORRAS. These folks grabbed attention with their Q3 Air and Q3 Air Pro cases, crafted for iPhone 18 Pro...

Continue Reading
Swanson Nexus Pro Launch: Boost for Dietitians

Updated Category News Views 195

Swanson Enters the Education Arena for Nutritionists Swanson Vitamins is mixing things up again! This time, they're launching something called Swanson Vitamins Nexus Pro, aimed squarely at the registered dietitians and licensed nutritionists crowd. Starting out as the place to grab your basic vitamins, Swanson's not resting on their supplement laurels. No, siree. They've...

Continue Reading
Innovent's IBI3001 Shows Promise in Phase 1 Trials

Updated Category News Views 164

Pioneering Path with IBI3001 at ESMO 2026 Navigating through the crowded landscape of oncology trials, Innovent Biologics recently rolled out some riveting Phase 1 clinical data for their new darling, IBI3001. Top brass from Innovent took to the European Society for Medical Oncology (ESMO) Congress stage to lay bare their findings. Obviously, when you're presenting a...

Continue Reading
World Young Scientist Summit 2026 in Wenzhou Kicks Off

Updated Category News Views 208

Young Minds Meet AI Innovation Crack open the playbook, and it's clear: young brains from across the globe are gathering in Wenzhou, Zhejiang, China, to wrangle with AI and chart the course of science toward a sustainable future. The World Young Scientist Summit 2026 isn't just a parade of speeches and accolades. Nah, it's a deep dive into where innovative minds believe...

Continue Reading
Wenda Pharma's NHWD-870 HCl Shows Promise in Trial

Updated Category News Views 237

Breaking Through in NUT Carcinoma Treatment Imagine battling an aggressive disease with barely any options left, and then something hopeful shows up in the pipeline. That's the story with Zhejiang Wenda Pharma's NHWD-870 HCl, an oral BET inhibitor making waves at the 2026 ESMO Annual Meeting. Facing off against the nasty beast that is NUT carcinoma, this drug didn't just...

Continue Reading

Top 5 Most Recently Viewed Articles

Exploring Precious Metals and Energy Investors' Strategies

Updated Category News Views 143

Current Trends in Precious Metals The appeal of precious metals like gold and silver continues to gather momentum, particularly in light of recent global events. Many analysts believe that geopolitical tensions have created a catalyst for increased interest in gold as a safe haven. As governments grapple with economic challenges, investors are keenly observing changes in...

Continue Reading
Understanding P/E Ratios in the Context of Casey's General Stores

Updated Category News Views 175

Analyzing P/E Ratios for Investment Decisions In today’s market, understanding the performance metrics of stocks is vital. Currently, Casey's General Stores Inc. (NASDAQ: CASY) is noted at an impressive share price of $536.66. This reflects a modest increase of 0.33%. In examining market trends, the past month saw a slight decline of 4.39% in share value. However,...

Continue Reading
China's New Lending Outlook: Economic Recovery Strategies

Updated Category News Views 135

China's Recent New Lending Trends Recent updates reveal a significant rise in new bank lending in China. However, it didn't quite meet expectations, as analysts had hoped for a stronger performance. After disappointing figures in July, which hit a 15-year low, new data shows that Chinese banks issued around 900 billion yuan (approximately $126.86 billion) in new loans in...

Continue Reading
ParkOhio Shares Important Quarterly Dividend News for Investors

Updated Category News Views 177

ParkOhio Holdings Announces Latest Dividend Declaration Park-Ohio Holdings Corp. (NASDAQ: PKOH) recently declared a significant quarterly cash dividend of $0.125 per share to its common stockholders. This distribution demonstrates the company's ongoing commitment to providing returns to its shareholders. This dividend will be payable soon, marking another positive...

Continue Reading
Investigation Launched for Tourmaline Bio's Shareholders

Updated Category News Views 259

Investigation Overview on Tourmaline Bio, Inc. Recently, Monteverde & Associates PC, a renowned law firm, has initiated an investigation concerning Tourmaline Bio, Inc. (NASDAQ: TRML) and its proposed sale to Novartis AG. This potential acquisition raises several questions about the fairness of the deal, specifically regarding the cash payment offered to shareholders....

Continue Reading